Combination Therapy for EGFR-Mutated Lung Cancer

Targeted therapy has improved prognoses for patients with advanced non–small-cell lung cancer (NSCLC) that has epidermal growth factor receptor (EGFR) mutations. The seminal trial that established precision medicine for EGFR-mutated NSCLC was the Iressa Pan-Asia Study (IPASS),1 and a second trial, AURA3, showed that resistance mutations could be detected and then targeted with osimertinib.2 FLAURA was an important third trial that moved osimertinib to the first line of treatment by showing delayed resistance and improved clinical outcomes; progression-free survival was 18.9 months, and overall survival was 38.6 months.3,4 Osimertinib became the standard therapy for advanced NSCLC with EGFR-sensitive mutations. The story . . .